Back to top

Inhibikase Therapeutics IKT-001 gets Orphan Drug Designation from FDA

Inhibikase Therapeutics (IKT) announced that the FDA has granted Orphan Drug Designation to its lead product candidate IKT-001, a prodrug of imatin...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Inhibikase Therapeutics, Inc. (IKT)